ArticleClinical and vaccine immunology : CVI2012
Chronic hepatitis C virus infection breaks tolerance and drives polyclonal expansion of autoreactive B cells.
Article in Clinical and vaccine immunology : CVI, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 22 citations in OpenAlex.
- Autoantibodies to apolipoprotein A-I in hepatitis C virus infection: a role in disease progression?Frontiers in immunology · 2025Article
- Review
- Polymorphisms in the TGFB1 and FOXP3 genes are associated with the presence of antinuclear antibodies in chronic hepatitis C.Heliyon · 2020Article
- Pseudotyping retrovirus like particles vaccine candidates with Hepatitis C virus envelope protein E2 requires the cellular expression of CD81.AMB Express · 2019Article
- Genetic and structural insights into broad neutralization of hepatitis C virus by human VScience advances · 2019Article
- Abnormal phenotypic features of IgM+B cell subsets in patients with chronic hepatitis C virus infection.Experimental and therapeutic medicine · 2017Article
- Type I interferon suppresses virus-specific B cell responses by modulating CD8Science immunology · 2016Article
- T cell-dependent IgM memory B cells generated during bacterial infection are required for IgG responses to antigen challenge.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
- Autoimmunity and infection in Sjögren's syndrome.Current opinion in rheumatology · 2013Review
- Immunity and hepatitis C: a review.Current HIV/AIDS reports · 2013Review
- Molecular signatures of hepatitis C virus (HCV)-induced type II mixed cryoglobulinemia (MCII).Viruses · 2012Review
- Hepatitis C virus infection and autoimmune diseases.International journal of general medicine · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Chronic Hepatitis C virus (HCV) infection has been linked with B cell lymphoproliferative disorders and several autoimmune-related diseases. The mechanisms of how chronic viral infection affects B cell development and predisposes the patients to autoimmune manifestations are poorly understood. In this study, we established an experimental system to probe the B cell responses and characterize the antibodies from chronic-HCV-infected individuals. We identified an unusual polyclonal expansion of the IgM memory B cell subset in some patients. This B cell subset is known to be tightly regulated, and autoreactive cells are eliminated by tolerance mechanisms. Genetic analysis of the immunoglobulin (Ig) heavy chain variable gene (V(H)) sequences of the expanded cell population showed that the levels of somatic hypermutation (SHM) correlate with the extent of cell expansion in the patients and that the V(H) genes exhibit signs of antigen-mediated selection. Functional analysis of the cloned B cell receptors demonstrated autoreactivity in some of the expanded IgM memory B cells in the patients which is not found in healthy donors. In summary, this study demonstrated that, in some patients, chronic HCV infection disrupts the tolerance mechanism that normally deletes autoreactive B cells, therefore increasing the risk of developing autoimmune antibodies. Long-term follow-up of this expanded B cell subset within the infected individuals will help determine whether these cells are predictors of more-serious clinical manifestations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.